Data presented at tct reinforce edwards lifesciences' commitment to structural heart innovation

Washington--(business wire)--edwards lifesciences (nyse: ew) today announced significant additions to the body of high-quality evidence presented and published during the transcatheter cardiovascular therapeutics (tct) conference, addressing the critical needs of patients with structural heart disease. “the data at tct on edwards' innovations underscore our commitment to scientific leadership and our focus to bring impactful and life-saving structural heart therapies to patients and physicians,.
EW Ratings Summary
EW Quant Ranking